Barcelona, 4 October 2007.- Almirall announces the appointment of Klaus Melchers as Senior Discovery Director reporting to the Executive Director for the R&D Area, Dr. Per Olof Andersson. This appointment is a move to strengthen Almirall’s drug discovery and a further example of the company´s commitment to the development of its R&D area.
Taking on this position Dr. Melchers brings with him extensive experience in the pharmaceutical industry, in basic and preclinical research, in therapeutic areas such as gastroenterology, oncology and respiratory diseases.
Klaus Melchers has a doctorate in Molecular Biology from the Ruhr-University Bochum in Germany. He started his career at the German division of Altana Pharma (now Nycomed) in 1987 and, from 2002 until recently, he has held the positions of the Vice President and Chief Operating Officer of the Altana Research Institute in Boston, Massachusetts (USA). In this function he directed genomics research for identification of novel drug targets and drug discovery programmes with a strong focus on mast cell biology and respiratory diseases.
About Almirall
Almirall, an international pharmaceutical company committed to health, headquartered in Barcelona, Spain, researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people’s health and wellbeing.
The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), psoriasis, rheumatoid arthritis and multiple sclerosis.
Almirall is currently present in over 80 countries. The company has direct presence in Europe and Latin America via affiliates in France, Germany, Italy, Portugal, Belgium and Mexico.
Para más información:
Ketchum/SEIS
Sonia San Segundo / Victoria Hernández
sonia.sansegundo@ketchum.com
Tel.: 91 788 32 00
